Ciprofloxacin Hydrochloride Solution/ Drops
NDC Package 68071-4235-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Ciprofloxacin Hydrochloride solution/ dropses is ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:Corneal Ulcers: Pseudomonas aeruginosaSerratia marcescens*Staphylococcus aureusStaphylococcus epidermidisStreptococcus pneumoniaeStreptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzaeStaphylococcus aureusStaphylococcus epidermidisStreptococcus pneumoniae*Efficacy for this organism was studied in fewer than 10 infections. This formulation utilizes a solution/ drops delivery system. Marketed by Nucare Pharmaceuticals,inc., this product is identified by NDC 68071-4235 and is authorized under FDA application NDA019992.

Identification & Billing

NDC Package Code
68071-4235-3
Package Description
2.5 mL in 1 BOX
Product Code
11-Digit Billing Format
68071423503
RxNorm Crosswalk
  • RxCUI: 309307 - ciprofloxacin HCl 0.3 % Ophthalmic Solution
  • RxCUI: 309307 - ciprofloxacin 3 MG/ML Ophthalmic Solution
  • RxCUI: 309307 - ciprofloxacin 0.3 % Ophthalmic Solution
  • RxCUI: 309307 - ciprofloxacin 3 MG/ML (as ciprofloxacin hydrochloride 3.5 MG/ML) Ophthalmic Solution

Clinical Specifications

Proprietary Name
Ciprofloxacin Hydrochloride
Non-Proprietary Name
Ciprofloxacin Hydrochloride
Substance Name
Ciprofloxacin Hydrochloride
Dosage Form
Solution/ Drops - A solution which is usually administered in a drop-wise fashion.
Administration Route
Ophthalmic - Administration to the external eye.
Usage Information
Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below:Corneal Ulcers: Pseudomonas aeruginosaSerratia marcescens*Staphylococcus aureusStaphylococcus epidermidisStreptococcus pneumoniaeStreptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzaeStaphylococcus aureusStaphylococcus epidermidisStreptococcus pneumoniae*Efficacy for this organism was studied in fewer than 10 infections.

Regulatory & Marketing

Labeler Name
Nucare Pharmaceuticals,inc.
Product Type
Human Prescription Drug
FDA Application #
NDA019992
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
05-07-2004
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68071-4235-3 identifies a specific commercial package of 2.5 ml in 1 box of Ciprofloxacin Hydrochloride, a human prescription drug labeled by Nucare Pharmaceuticals,inc.. This solution/ drops is formulated for ophthalmic use and contains ciprofloxacin hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nucare Pharmaceuticals,inc. on May 07, 2004. The current certification is valid through December 31, 2026.

How is this Nucare Pharmaceuticals,inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68071423503. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68071-4235-3
11-Digit CMS (5-4-2)
68071-4235-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.